top of page
BPIQ Blog
Jan 17, 20233 min read
Upcoming Gastrointestinal Cancer Events - PDUFA and ASCO-GI Conference this Week!
Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal...
Jan 13, 20231 min read
Biopharma Pulse - 1/9-1/13 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Jan 13, 20232 min read
Pro Biotech Catalyst Watchlist Jan 15th 2022
Last week we saw a number of buyouts and saw the JP Morgan conference. As we continue to move through this quarter we see a number of...
Jan 13, 20232 min read
Biotech Catalyst Watchlist Jan 15th 2022
Last week we saw a number of buyouts and had the JP Morgan conference. As we move through this quarter we see a number of PDUFA events...
Jan 12, 20231 min read
Stock Market Holidays in 2023
See Table 1 for all Stock Market Holidays where the NASDAQ stock market is closed. Table 1. Stock market holidays in 2023 If you are...
Jan 11, 20233 min read
Is MDGL Resmetirom Data Superior to Previous NASH Data?
Last updated 1/12/2023 Summary: MDGL read out Phase 3 topline data on December 19, leading to a stock move of over +250%! Many other NASH...
Jan 6, 20231 min read
Biopharma Pulse - 1/3-1/6 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Jan 6, 20232 min read
Pro Biotech Catalyst Watchlist Jan 8th 2022
We ended the previous week with the FDA approval for Lecanemab treating Alzheimer's. We'll track and share the future events as they...
Jan 6, 20232 min read
Biotech Catalyst Watchlist Jan 8th 2022
We ended the previous week with the FDA approval for Lecanemab treating Alzheimer's. We'll track and share the future events as they...
Jan 6, 20233 min read
BPIQ's Smid-Cap Biopharma 2022 Year in Review
Summary: The biotech sector saw many exciting events and readouts in 2022 While smid-cap biopharmas were down more than 20% during 2022,...
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page